The benefits of receiving AstraZeneca COVID-19 vaccine outweigh the risk of side effects, the European Medicines Agency (EMA) announced on Wednesday, confirming that blood clots should be listed as “very rare side effects” of this product.
COVID-19: Poland may mass-produce vaccine in Q3
“The risk of dying from COVID-19 is much higher than the risk of dying from the side effects of the vaccine. These preparations help us in the fight against the virus and we must continue to administer them,” Emer Cooke, the head of the European Medicines Agency (EMA) said.
The EMA has reported very rare cases of blood clots in combination with low levels of platelets in the two weeks following vaccination with this medicine.
“To date, the majority of reported cases have occurred among women under 60 years of age within two weeks of vaccination. Specific risk factors have not been confirmed based on the evidence currently available,” the EMA reported.
Out of the 43 million people vaccinated with the AstraZeneca product in the European Union and the United Kingdom, complications occurred among around two hundred individuals, 18 of whom died.
Earlier in April, the government announced it would like people aged 60 or older to be vaccinated until the end of April. Michał Dworczyk, the Head of the Office of the Prime Minister and the government’s plenipotentiary for the National Vaccination Programme, appealed to vaccination points to inoculate these people sooner than originally planned.